Login to Your Account



Sweet deal for Gilead? Firm snaps up Sarepta's PRV for $125M cash

By Michael Fitzhugh
Staff Writer

Tuesday, February 21, 2017

Duchenne muscular dystrophy specialist Sarepta Therapeutics Inc. gained $125 million by selling to Gilead Sciences Inc. an FDA priority review voucher (PRV) won with its approval of Exondys 51 (eteplirsen).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription